Success Stories

View all: Success Stories

ClinSpec Dx

ClinSpec Dx, a spin-out from the University of Strathclyde and 2017 Converge Challenge runner-up, is pioneering a new blood test that can detect brain tumors rapidly, allowing for early diagnosis.

Founded by Dr Holly Butler and Dr Matt Baker, the company uses revolutionary technology to provide accurate results in minutes.

With proof-of-concept and commercial / health viability tests complete, ClinSpec Dx is now undergoing diagnostic accuracy studies at Western General Hospital, Edinburgh, with an anticipated roadmap to commercial launch in 2021.